hr+ her2+ breast cancer

Release time ：Dec-27,2024

HR-positive/HER2-positive breast cancer is a distinct subtype of breast cancer, defined by an abundance of human epidermal growth factor receptor 2 (HER2) protein on the tumor cell surface and responsiveness to hormonal stimuli. While this subtype tends to be more aggressive than other breast cancer types, advancements in HER2-targeted therapies have significantly improved treatment options for affected patients.

Treatment for HR-positive/HER2-positive breast cancer often involves a multidisciplinary approach. Surgery is typically the first-line treatment, which may include lumpectomy or mastectomy. Following surgery, radiation therapy may be administered to reduce the risk of local recurrence, contingent upon the patient's specific condition. Chemotherapy is also a common treatment to eliminate any remaining cancer cells. Given the HER2-positive nature of the disease, patients may undergo targeted therapy with drugs like trastuzumab (Herceptin), designed to block the HER2 protein and thus inhibit tumor growth. For patients with hormone receptor positivity, endocrine therapy is an important adjunct, functioning by blocking estrogen to suppress tumor proliferation.

Patients diagnosed with HR-positive/HER2-positive breast cancer should vigilantly monitor their health and engage in regular follow-ups and testing. Any new or unusual symptoms should prompt immediate medical consultation, with full disclosure of medical history and treatment background to the healthcare provider. Throughout treatment, adherence to the physician's directives is crucial, including timely completion of all treatment regimens and awareness of potential drug side effects and interactions. Additionally, maintaining healthy lifestyle practices such as a balanced diet, regular physical activity, and abstaining from smoking and excessive alcohol consumption can enhance treatment efficacy and overall quality of life.